SemiAlloGen offers preventative and therapeutic solutions for a variety of cancers and neurodegenerative disorders, using personalized cellular medicine for peace of mind.  SemiAlloGen technology has a wide range of applications and anticipates current and future demographic trends.  The SemiAlloGen vaccine platform is based on proprietary technology for manufacturing unlimited amounts of personalized cellular medicines to meet the unique needs of everyone's own genetic make-up, including genetic predisposition to cancer and neurodegenerative diseases.

Dr. Gattoni-Celli and Dr. Kindy were interviewed by Dennis Quick of the Charleston Business Journal

CHARLESTON -- Last year, Dr. Sebastiano Gattoni-Celli and Mark Kindy, both of the Medical University of South Carolina, launched SemiAlloGen Inc., a biotech company developing vaccines and therapeutic treatments for Alzheimer’s disease and cancer...

Read the full article here.